Lifeward (NASDAQ:LFWD) Posts Quarterly Earnings Results, Misses Estimates By $0.66 EPS

Lifeward (NASDAQ:LFWD) issued its quarterly earnings data on Friday. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.66), FiscalAI reports. Lifeward had a negative return on equity of 235.86% and a negative net margin of 141.28%. The business had revenue of $5.43 million during the quarter, compared to the consensus estimate of $7.24 million.

Lifeward Price Performance

NASDAQ LFWD traded down $1.66 on Friday, reaching $4.06. The company’s stock had a trading volume of 30,374 shares, compared to its average volume of 14,890. Lifeward has a twelve month low of $3.81 and a twelve month high of $9.61. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.77 and a current ratio of 2.33. The firm’s 50 day moving average is $6.42 and its two-hundred day moving average is $6.87. The stock has a market cap of $11.49 million, a PE ratio of -0.24 and a beta of 0.55.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LFWD. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Lifeward in a research note on Friday, August 21st. Citigroup reissued a “buy” rating on shares of Lifeward in a research note on Friday, August 21st. Zacks Research raised Lifeward from a “strong sell” rating to a “hold” rating in a report on Monday, July 27th. Finally, Weiss Ratings upgraded shares of Lifeward from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.00.

Lifeward Company Profile

Lifeward Ltd. (NASDAQ: LFWD) is a medical technology company focused on developing and commercializing wearable robotic systems designed to help people with mobility impairments stand, walk and participate in rehabilitation. The company was formerly known as ReWalk Robotics and adopted the Lifeward name in 2024. Lifeward’s principal product line is the ReWalk Personal Exoskeleton, a battery-powered wearable robotic device intended to enable individuals with lower-limb disabilities, including those resulting from spinal cord injury, to walk with the assistance of crutches or other support.